Global Sexual Dysfunction Drugs Market 2017-2021

性機能障害治療薬の世界市場2017-2021:経口、静脈内、ホルモン療法、経尿道

◆タイトル:Global Sexual Dysfunction Drugs Market 2017-2021
◆商品コード:IRTNTR14890
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2017年8月31日
◆ページ数:91
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:Healthcare and Life Sciences
◆販売価格オプション(消費税別)
Single User(1名利用)USD3,500 ⇒換算¥395,500見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥565,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

Technavio社が発行した当調査レポートでは、性機能障害治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、疾患概要、性機能障害治療薬の世界市場規模及び予測、地域別分析/市場規模、市場の成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。Technavio社は性機能障害治療薬の世界市場が2017-2021年期間中に年平均2.79%成長すると予測しています。当レポート上に記載されている主な企業はAbbVie、Bayer、Eli Lilly、Pfizer等です。

About Sexual Dysfunction Drugs
Sexual dysfunctions include sexual disorders of men and women that can interfere with their sexual performance, leading to unsatisfied sexual intercourse. The major drugs used in this market are PDE5 inhibitors, whereas other drugs such as hormone-related and transurethral also have a presence in the market. Erectile dysfunction (ED) is a highly prevalent sexual dysfunction seen in men. Globally, there has been an increase in the number of ED cases caused due to high blood pressure, obesity, neurological and nerve disorders, prostate cancer, and diabetes among others.

Technavio’s analysts forecast the global sexual dysfunction drugs market to grow at a CAGR of 2.79% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global sexual dysfunction drugs market for 2017-2021. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Sexual Dysfunction Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• AbbVie
• Bayer
• Eli Lilly
• Pfizer

[Other prominent vendors]
• Apricus Biosciences
• Emotional Brain
• GlaxoSmithKline
• Ivix LLX
• Leadiant Biosciences
• Merck
• NexMed
• Palatin Technologies and PRA Health Sciences
• S1 Biopharma
• Takeda
• Teva Pharmaceutical Industries
• Trimel Biopharma SRL
• Vietstar Biomedical Research

[Market driver]
• Rising prevalence of sexual dysfunctions
• For a full, detailed list, view our report

[Market challenge]
• Technological advancements, a threat to drug therapy
• For a full, detailed list, view our report

[Market trend]
• Increased focus on generic drugs
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?

*** You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

Table of Contents
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
• Market outline

PART 05: Disease overview
• Sexual dysfunction: Definition
• Causes of sexual dysfunction

PART 06: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 07: Pipeline

PART 08: Market segmentation by therapy
• Oral therapy
• Intracavernosal therapy
• Hormonal therapy
• Transurethral therapy

PART 09: Geographical segmentation
• Sexual dysfunction drugs market in Americas
• Sexual dysfunction drugs market in EMEA
• Sexual dysfunction drugs market in APAC

PART 10: Decision framework

PART 11: Drivers and challenges
• Market drivers
• Market challenges

PART 12: Market trends
• Increased focus on generic drugs
• Migration of manufacturing and sales facilities to APAC
• Advancing biomedical science

PART 13: Vendor landscape
• Competitive scenario

PART 14: Key vendor analysis
• AbbVie
• Bayer
• Eli Lilly
• Pfizer
• Other prominent members

PART 15: Appendix
• List of abbreviations

[List of Exhibits]
Exhibit 01: Symptoms of sexual dysfunction in men and women
Exhibit 02: Types of sexual disorder
Exhibit 03: Causes of sexual dysfunction
Exhibit 04: Regional prevalence rate of ED June 2016
Exhibit 05: Global sexual dysfunction drugs market: Snapshot
Exhibit 06: Global sexual dysfunction drugs market 2016-2021 ($ millions)
Exhibit 07: Key drugs patent expiration in major countries
Exhibit 08: Opportunity analysis of global sexual dysfunction drugs market
Exhibit 09: Five forces analysis
Exhibit 10: Pipeline snapshot based on number of molecules 2016
Exhibit 11: Pipeline snapshot based on types of sexual dysfunction 2016
Exhibit 12: Key clinical trials
Exhibit 13: Global sexual dysfunction drugs market segmentation by therapy 2016
Exhibit 14: Oral therapies used as per drug class
Exhibit 15: Global sexual dysfunction oral drugs market 2016-2021 ($ millions)
Exhibit 16: Intracavernosal therapy used as per drug class
Exhibit 17: Global sexual dysfunction intracavernosal drugs market 2016-2021 ($ millions)
Exhibit 18: Some marketed intracavernosal drugs
Exhibit 19: Hormonal therapy used as per drug class
Exhibit 20: Global sexual dysfunction hormonal drugs market 2016-2021 ($ millions)
Exhibit 21: Transurethral therapy used as per drug class
Exhibit 22: Global sexual dysfunction transurethral drugs market 2016-2021 ($ millions)
Exhibit 23: Global sexual dysfunction drugs market share by geography 2016 and 2021
Exhibit 24: Global sexual dysfunction drugs market revenue by geography 2016-2021
Exhibit 25: Global sexual dysfunction drugs market share by geography 2016-2021
Exhibit 26: Snapshot of Global sexual dysfunction drugs market by geography 2016 and 2021
Exhibit 27: Market scenario in Americas
Exhibit 28: Sexual dysfunction drugs market in Americas 2016-2021 ($ millions)
Exhibit 29: Market scenario in EMEA
Exhibit 30: Sexual dysfunction drugs market in EMEA 2016-2021 ($ millions)
Exhibit 31: Market scenario in APAC
Exhibit 32: Sexual dysfunction drugs market in APAC 2016-2021 ($ millions)
Exhibit 33: Prevalence data of sexual dysfunction in women and men every year
Exhibit 34: Geriatric population analysis and estimates 2000 and 2030 (millions)
Exhibit 35: Mean number of prostate cancer diagnoses by five-year age band 2008-2010
Exhibit 36: Prevalence of ED in stroke patients 2008
Exhibit 37: Competitive structure analysis of global sexual dysfunction drugs market 2016
Exhibit 38: AbbVie: Key highlights
Exhibit 39: AbbVie: Strength assessment
Exhibit 40: AbbVie: Strategy assessment
Exhibit 41: AbbVie: Opportunity assessment
Exhibit 42: Bayer: Key highlights
Exhibit 43: Bayer: Strength assessment
Exhibit 44: Bayer: Strategy assessment
Exhibit 45: Bayer: Opportunity assessment
Exhibit 46: Eli Lilly: Key highlights
Exhibit 47: Eli Lilly: Strength assessment
Exhibit 48: Eli Lilly: Strategy assessment
Exhibit 49: Eli Lilly: Opportunity assessment
Exhibit 50: Pfizer: Key highlights
Exhibit 51: Pfizer: Strength assessment
Exhibit 52: Pfizer: Strategy assessment
Exhibit 53: Pfizer: Opportunity assessment



【掲載企業】

AbbVie, Bayer, Eli Lilly, Pfizer, Apricus Biosciences, Emotional Brain, GlaxoSmithKline, Ivix LLX, Leadiant Biosciences, Merck, NexMed, Palatin Technologies and PRA Health Sciences, S1 Biopharma, Takeda, Teva Pharmaceutical Industries, Trimel Biopharma SRL, Vietstar Biomedical Research


★調査レポート[性機能障害治療薬の世界市場2017-2021:経口、静脈内、ホルモン療法、経尿道] (Global Sexual Dysfunction Drugs Market 2017-2021 / IRTNTR14890)販売に関する免責事項
[性機能障害治療薬の世界市場2017-2021:経口、静脈内、ホルモン療法、経尿道] (Global Sexual Dysfunction Drugs Market 2017-2021 / IRTNTR14890)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆